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Summary 
 
 Molecular genetic analysis indicates that the problematic human bacterial pathogen 
methicillin-resistant Staphylococcus aureus (MRSA) possesses more than 2,000 open reading 
frames in its genome. This number of potential gene products, coupled with intrinsic 
mechanisms of posttranslational modification, endows MRSA with a highly complex 
biochemical repertoire. Recent proteomic and metabolomic advances have provided 
methodologies to better understand and characterize the biosynthetic factors released by 
microbial organisms. Here, the emerging tool of mass spectrometry-based molecular networking 
was used to visualize and map the repertoire of biosynthetic factors produced by a community-
associated MRSA strain representative of the epidemic USA300 clone.  In particular, the study 
focused on elucidating the complexity of the recently discovered phenol soluble modulin (PSM) 
family of peptides when placed under various antibiotic treatment stresses. Novel PSM truncated 
variant peptides were captured, and the type of variants that were clustered by the molecular 
networks platform changed in response to the different antibiotic treatment conditions. After 
discovery, a group of the peptides were selected for functional analysis in vitro. The peptides 
displayed bioactive properties including the ability to induce proinflammatory responses in 
human THP-1 monocytes. Additionally, the tested peptides did not display antimicrobial activity 
as previously reported for other PSM truncated variants. Our findings reveal that the PSM family 
of peptides are quite structurally diverse, and suggest a single PSM parent peptide can 
functionally spawn differential bioactivities in response to various external stimuli. 
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INTRODUCTION 
A significant percentage of the human population harbors Staphylococcus aureus as a 
natural resident of their microbial flora (1). In non-infected individuals, S. aureus maintains a 
homeostatic coexistence with neighboring microbes and with the host (2). However, when 
equilibrium is disrupted, S. aureus is capable of establishing diseases ranging from minor 
superficial infections to potentially life-threatening invasive conditions (3, 4). Through the 
discovery and administration of antibiotics, clinicians have significantly reduced the morbidity 
and mortality associated with S. aureus (5, 6). In recent years, the consequences of persistent 
antibiotic exposure have become increasingly manifest through the emergence of resistant strains, 
including those left unperturbed by methicillin and related β-lactam antibiotics (MRSA) or those 
with intermediate or full resistance to vancomycin (VISA/VRSA) (7). Certain drug-resistant S. 
aureus strains, such as the USA300 clone, have spread beyond the hospital setting and into the 
community, producing serious infections even in previously healthy individuals (8, 9). Both 
community-associated (CA) and hospital-associated (HA) multi-drug resistant S. aureus are 
highly evolved, multifaceted pathogens that pose an increasing threat to the health of not only 
our own, but future generations as well.  
The pathogenic mechanisms of S. aureus have been examined extensively through 
different stages of infection (10, 11), with an improved understanding of specific functions that 
various staphylococcal components contribute to virulence (12). The ability to outcompete other 
microflora for colonization, or to circumvent the host immune response during infectious spread, 
largely reflects a complex network of proteins and non-protein molecules that S. aureus secretes 
into its surroundings–which may collectively be termed biosynthetic release factors. One 
component of this network is the newly studied and multifunctional phenol soluble modulin 
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(PSM) family of peptides. Associated with biofilm formation and possessing bioactivity toward 
host cells, PSMs are produced more abundantly by CA-MRSA compared to HA-MRSA strains 
(13, 14). PSMs are biosynthesized and released with formylated initiator methionine, allowing 
binding and activation of host neutrophils via the formyl peptide receptor 2 (FPR2) (15). A 
number of PSMs show cytolytic properties toward host cell lines, and supporting this, isogenic 
PSM-knockout mutants have decreased virulence in murine models of invasive infection (13). 
Recently, it was found that many in vitro PSMs phenotypes (e.g. neutrophil lysis, FPR2 binding) 
were strongly inhibited by serum lipoproteins (16). The same study showed upregulation of PSM 
biosynthesis following phagocytosis, suggesting an important role in intracellular survival. 
Additionally, N-terminal truncated derivative forms of PSMs (dPSMs) with antibacterial 
properties were identified (17, 18). The finding that dPSMs possess antibacterial activities that 
are absent in the corresponding full-length parent PSMs, inspired a hypothesis that dPSMs 
endow CA-MRSA strains with a competitive advantage against resident microbiota upon 
colonizing host epithelia (i.e. once truncated PSMs gain antimicrobial properties). 
The invaluable tool of mass spectrometry (MS) has played a major role in characterizing 
biosynthetic release factors for a diverse number of organisms (19). Over the past decade, the 
field has spawned several innovative methods to optimize data collection, processing, and 
organization. The advancement of MS processing methods has improved the capabilities for 
extracting significant information regarding an organism’s biochemical repertoire. One emerging 
tool to study biosynthetic release factor potential is the tandem MS data processing program, 
Spectral Networks. In conjunction with Cytoscape graphical mapping, Spectral Networks allows 
for the construction of a molecular network map that gives a visualization of tandem mass 
spectra grouping, based on similar scoring of overlapping ion fragmentation patterns (20, 21). 
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The matching of spectra, termed spectral pairing, is unlike the conventional mode of processing 
MS data by matching against a reference library or specifying specific posttranslational 
modifications for identification (22). Instead, within a molecular network map, ion fragmentation 
patterns can be represented by correlation points, displayed as circular nodes, connected with a 
straight line to other nodes containing high similarity scores. The power of molecular networking 
is the information provided on tandem MS subpopulation clusters, which represent structurally 
matching but variant protein or non-protein biosynthetic release factors. 
In this work, the MS-based molecular networking platform was applied to a 
representative strain of the epidemic CA-MRSA USA300 clone. The study sought to provide 
insight into the biosynthetic release factor map of this pre-eminent human bacterial pathogen 
under normal growth and antibiotic challenged conditions. Biologically relevant pharmacological 
stimuli studied included sub-inhibitory concentrations of commonly prescribed commercial 
antibiotics as well as the innate human defense peptide LL-37 (23-25). In particular, our study 
goal was to monitor any variations in the type of dPSMs clustered within the molecular network 
map in response to these stimuli. We show an enriched extract derived from CA-MRSA alone or 
under these specific challenge conditions provides a highly complex biosynthetic release factor 
map. Analysis of subpopulation node clusters associated with PSMs prompted the discovery of 
several previously unreported α, β, and γ type dPSMs. The antibiotic stimuli modulated the type 
of dPSMs clustered, allowing for differential subclusters to be visualized that were absent in the 
untreated sample; including nodes that did not sequence to proteogenic PSMs. A group of the 
newly discovered PSM variants were assessed for functional properties and showed the induction 
of proinflammatory responses in THP-1 cells. In addition, in contrast to previous reports (17, 18), 
the tested dPSMs did not display antimicrobial activity. We conclude MS-based molecular 
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networking can be used as a targeted discovery tool with the ability to identify previously 
unreported bioactive peptides. 
 
EXPERIMENTAL PROCEDURES 
 Bacterial Strain and Culture Conditions. S. aureus USA300 strain TCH1516 (26) alone 
or in the presence of (i) 0.125 mg/L daptomycin, (ii) 0.125 mg/L vancomycin, or (iii) 1.2 mg/L 
LL-37 was grown in Todd Hewitt broth (THB) and propagated at 37°C. Growth curves were 
constructed on several occasions to ensure no significant changes were encountered between 
treated and untreated samples by monitoring the OD600 until reaching a robust cell density.  
 Sample Preparation for Nanocapillary Liquid Chromatography Tandem Mass 
Spectrometry (LC-MS/MS). Samples at equivalent OD600, along with a THB media alone control 
sample, were incubated at a 1:1 ratio with 1-butanol, mixed and allowed to separate into polar 
and nonpolar phases overnight. The solvent 1-butanol was used to selectively capture small 
molecules and peptides. The samples were then centrifuged at 2,000 rpm for 5 min and the layer 
containing 1-butanol was collected in 1 ml portions. These were each centrifuged at 14,000 rpm, 
transferred to a new container, and brought to complete dryness by SpeedVac centrifuge. Two 
sample tubes for each experiment were then resuspended and pooled before passing samples 
through a size-exclusion column. Collected fractions were brought to complete dryness and 
stored. Synthetic PSMα4 (American Peptide Co) of >95 % purity was also processed as a control 
to ensure the method per se did not alter the peptide nor create variant forms.  
 Nanocapillary LC-MS/MS. Nanocapillary columns were prepared by splitting 
deactivated, fused silica tubing (Agilent) with a model P-2000 laser puller (Sutter Instruments). 
Pulled 15 cm columns were packed with C18 reverse phase resin suspended in methanol. 
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Thereafter, the column was mounted onto the LC-MS/MS apparatus and equilibrated with 95% 
solvent A (water, 0.1% formic acid) until a stable ion chromatogram was achieved. A gradient 
for loading and eluting extract contents was established with a time-varying mixture of solvent A 
and B (acetonitrile, 0.1% formic acid) and electrosprayed directly into a calibrated Thermo 
Finnigan LTQ-XL. Acquisition parameters included data-dependent ion selection targeting the 
first to fifth most abundant ions in the parent mass spectrum for fragmentation. Data sets for the 
extracted samples were collected in the following order: (i) ESI solvent (ii) THB media (iii) CA-
MRSA untreated (iv) CA-MRSA + daptomycin (v) CA-MRSA + vancomycin (vi) CA-MRSA + 
LL-37. A water blank was run between samples to minimize overlapping contamination.  
 Construction of Molecular Networks. Molecular Networks were constructed as 
previously described (21). Briefly, collected .RAW files were converted to MZXML files by the 
program ReAdW. Converted files were then clustered at cosine scores of greater than or equal to 
0.6. The graphical display program Cytoscape was used to view clustered spectra as molecular 
networks based on tandem MS fragmentation patterns. In each Cytoscape map,  nodes that were 
found overlapping with both the CA-MRSA alone sample and also in the CA-MRSA plus 
antibiotic stimulus were colored grey. Nodes that were specific to CA-MRSA alone are colored 
gold. Nodes that were specific to the CA-MRSA plus daptomycin were colored aqua blue, those 
specific to CA-MRSA plus vancomycin colored green, and those specific to CA-MRSA plus 
LL-37 colored red. Nodes pertaining to components of THB media and LC-MS/MS solvents 
were filtered out from the networks to minimize false positive matching rates.  
 Identification of PSM derivatives. To identify network clusters related to PSMs, a 
targeted approach was taken displaying the parent ion mass of each individual node and 
matching according to theoretical values for full-length PSMs and truncated dPSMs.  Amino acid 
 8 
sequences pertaining to PSMs were obtained from previously published work (18). When an ion 
cluster was found that contained the mass indicative of PSMs or dPSMs and the specific node 
mass contained less than 450 ppm mass error (parent masses) relative to the theoretical value, de 
novo sequencing of the peptide was performed. PSMs are released extracellularly containing a 
formylated (+28 kDa) initiator methionine; when appropriate, the PTM was considered in the 
manual searches. Tandem mass spectra with a minimum of seven contingent ions of correct mass 
accuracy and fragment peaks with a mass tolerance of 0.5 Da were accepted as valid sequence 
tags. When a node was identified according to the set criteria, adjacent nodes were processed for 
identification purposes using the same criteria for validation. LC-MS/MS runs were performed in 
triplicate, with different growth experiments prepared on separate days using the same USA300 
CA-MRSA (TCH1516) strain stock. All analyzed nodes including sequence tags for newly 
discovered PSMs are provided in the Online Supplemental Information. 
 PSMs peptide levels monitored by Spectral Counts. To monitor the effect of relative PSM 
production in the presence of antibiotic stimulus, spectral counts for each indentified dPSM were 
enumerated by the use of InsPecT (20). Relevant input search parameters included the following: 
(i) post-translational modification search, +28 Da (formylation); (ii) database, modified 
TCH1516 USA300 genome, TCH1516 USA300 genome ‘reversed’, and common contaminants 
database; (iii) PTM allowed per peptide, 2; (iv) b- and y-ion mass offset tolerance, 0.5 Da; (v) 
parent mass tolerance, 1.5 Da. Statistical significance was determined by one way ANOVA with 
Tukey’s post-hoc test. ** indicates p < 0.01, *** indicates p < 0.001. 
Hemolysis activity. Defibrinated sheep blood was washed in PBS and diluted to a final 
concentration of 1:25. Washed blood was then placed into individual wells of a round-bottom 
96-well microtiter plate (Costar, Corning). dPSM peptides at a final concentration of 20 µg/ml, 
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10 µg/ml, 5 µg/ml or 1µg/ml were added directly to the wells. Thereafter, the plate was sealed by 
parafilm and incubated for 360 min and overnight at 37°C. After incubation, plates were 
centrifuged at 1600 rpm for 5 min, and 60 µl of supernatant (without disturbing pellet) was 
placed in a separate microtiter plate to measure hemoglobin absorbance at 450 nm on a 
microplate reader. Diluted Triton-X (0.0125%) was used as a positive control for hemolysis and 
1 x PBS was used as a negative control. Hemolysis was normalized to the Triton-X positive 
control, which was considered 100% hemolysis. 
Antimicrobial activity. The representative skin and soft tissue microbes Staphylococcus 
epidermidis ATCC36981, Staphylococcus epidermidis Nizet lab strain, Group A Streptococcus 
(GAS) serotype M3 and methicillin-sensitive Staphylococcus aureus (MSSA) ATCC29213 were 
incubated with 10 µg/mL or 1 µg/mL of the dPSM test peptides. Growth curves were monitored 
at an OD600 every 30 minutes until late exponential-stationary phase (OD600 ~0.8-1.0). Bacterial 
growth in medium without the dPSM peptides was used as control.  
 Immunostimulatory effects induced by the truncated PSM variants. THP-1 cells were 
grown in medium until confluent (RPMI, 10%FBS, 10mM HEPES, 1mM sodium pyruvate, 
D+glucose and 0.35‰ Basal Medium Eagle). THP-1 cells were seeded in 24-well plates with a 
final concentration of 5x105 cells/well and differentiated overnight with 25 nM PMA. New 
medium without PMA was added for 24 h before usage in successive experiments. The dPSM 
peptides were added with a final concentration of 20 µg/ml, 10 µg/ml, 5 µg/ml or 1 µg/ml 
respectively and cells were incubated at 37°C in a 5% CO2 incubator for 6 h. Cell culture 
medium was used as negative control and 10 µg/ml LPS or 0.01% Triton-X respectively, were 
used as positive control. Supernatant was harvested and stored at -20°C until used.  dPSM 
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peptide induced secretion of human IL-8 and IL-1β levels by THP-1 cells were measured by 
ELISA assay kits, according to manufacturer’s instructions (R&D Systems).  
 
RESULTS 
 
Building CA-MRSA Spectral Networks. Files were compiled and processed as a group to 
obtain consolidated files in the following manner: (i) CA-MRSA +/- daptomycin + THB media 
(ii) CA-MRSA +/- vancomycin + THB media (iii) CA-MRSA +/- LL-37 + THB media. 
Molecular Network maps were displayed by the use of Cytoscape graphical mapping, which 
displayed overlays of CA-MRSA alone and CA-MRSA plus antibiotic stimuli. In each case, ion 
signals derived from either the LC-MS/MS solvents or the THB media were subtracted from 
each overlay map. The Cytoscape map architecture is comprised of ion signals displayed as 
individual nodes that are clustered according to ion fragmentation similarity based on cosine 
scoring (20). Ion signals that have identical parent mass values and tandem MS fingerprints were 
grouped and displayed together as one signal node. Ion signals that had off-set parent masses and 
similar fragmentation patterns were displayed as connected nodes and grouped into clusters. The 
graphical layout was based on the mathematical modeling algorithm Fast Multipole Multilevel 
Method (FM3), which arranges similar nodes as straight-line connections in space representing 
correlation by proximity for graphical interpretation. The width of the straight-line connection 
indicates the cosine value between nodes and thus, similarity scoring (Fig. 1). In each case 
throughout this manuscript, nodes specific to CA-MRSA alone were colored gold, nodes specific 
to the CA-MRSA plus daptomycin were colored aqua blue, nodes specific to the CA-MRSA + 
LL-37 were colored red, and nodes specific to the CA-MRSA + vancomycin were colored green. 
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Overlapping nodes found in both CA-MRSA alone and when challenged with antibiotic were 
colored grey (Fig. 2a, 3a-b, 4a, 5a). 
CA-MRSA phenotypes at sub-MIC levels of antibiotics.  Several growth curves were 
generated to ensure that the treatment concentrations of antibiotics did not significantly alter 
normal growth of the CA-MRSA strain (supplemental Fig. S1a). Morphology and approximate 
counts of individual CA-MRSA cells were monitored by microscopy, with no distinguishable 
differences between the CA-MRSA control sample and samples grown with sub-MIC levels of 
antibiotics (supplemental Fig. S1b). Further, the 1-butanol extractions used to create the 
networks were examined by SDS-PAGE gel, with no observable large molecular bands on 
protein staining (gel not shown). Thus all observed MS signals were predicted to be low 
molecular weight peptides and small molecules. Analysis of synthetic PSMα4 (> 95% pure) with 
the same methodology +/- daptomycin did not produce any variant forms when checked by MS. 
Therefore, as previously reported (18), we hypothesize native proteases or other intrinsic 
mechanisms contribute to the processing of PSMs.  
Spectral Networks variants captured in PSMα1.  PSMα1 is a 21-mer formylated peptide 
that is biosynthetically produced and secreted in multi-variant forms by CA-MRSA. In vitro 
concentrations of secreted PSMα1 have been reported to vary depending on the S. aureus strain 
tested and media conditions (13). Prior experiments that monitored effects of sub-inhibitory 
antibiotic concentrations on PSMα1 production showed perturbations from baseline (27). To date, 
PSMα1 formylated and non-formylated forms have been detected in culture media, including 
two N-terminal truncated forms. The two variant forms were comparatively tested against full-
length formylated PSMα1 and showed a gain of antibacterial activity (17, 18). In our study, we 
searched for the theoretical intact masses of truncated PSMs within node clusters. Clusters that 
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had at least one node with a theoretical mass corresponding to dPSMα1 were separated and 
further analyzed. The node with correct theoretical mass accuracy was then sequenced de novo 
for identification. In those cases where a peptide sequence tag contained reasonable mass 
accuracy and greater than seven contingent amino acids, adjacent nodes were sequenced to 
complete the identification of the cluster. Fig. 2a shows two dPSMα1 nodal clusters constructed 
by merging the CA-MRSA untreated and daptomycin treated MS data sets. Within each cluster 
the grey individual nodes indicate overlapping spectra found in both settings, the blue nodes are 
represent spectra specific to daptomycin treatment and the gold nodes are spectra specific to the 
untreated sample. Each dPSMα1 node includes the acquired de novo sequence tags and mass off-
sets from the theoretical peptide sequence. In the CA-MRSA untreated sample, six dPSMα1 
variants were captured, including an N-terminus truncated 16-mer, 17-mer, 18-mer and a 19-mer. 
The 19-mer and 16-mer peptide variants have been previously described (17, 18). Two C-
terminal truncated dPSMα1 peptides, a 13-mer and a 14-mer, each with conserved formyl groups 
on the initiator methionine were also identified (Fig. 2b). Treatment of CA-MRSA with sub-
inhibitory daptomycin retained all captured variants except the previously described 16-mer 
formylated dPSMα1. Sub-inhibitory LL-37 and vancomycin treatment led to loss of the 13-mer 
dPSMα1 formylated peptide. In addition, vancomycin treatment had the most dramatic effect, as 
only the 19-mer, 18-mer, and 17-mer peptide dPSMα1 variants were detected (supplemental Fig. 
S2-S8). To assess false negatives as they pertain to the dPSMα1 detected by the MS-based 
molecular networking platform and to examine the relative production levels of dPSMα1 in 
response to antibiotics, spectral counts were enumerated. The overall trend for dPSMα1 when 
stimulated by each antibiotic treatment was an increase in peptide abundance; vancomycin 
showed the weakest stimulatory potential (supplemental Fig. S9). Consistent with the molecular 
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networks observation, the 13-mer formylated peptide was only detected in the untreated and 
daptomycin sample extracts by a traditional database search. Treatment with daptomycin 
significantly increased the spectral counts for the formylated 13-mer peptide (Fig. 2c). 
Spectral Networks variants captured in PSMα2.  Like PSMα1, PSMα2 is structurally 
comprised of 21 amino acids that share high homology at terminal ends. Cumulative studies on 
the abundance of biosynthetically released PSMα2 indicated low secretion in vitro relative to 
other PSMα peptides among strains tested (13). Full-length PSMα2 triggers phagocyte 
production of superoxide and permeates cell membranes in its mode of action (28). Two 
dPSMα2, a 19-mer peptide and a 16-mer, have been detected in different CA-MRSA strains (17, 
18). Fig. 3a shows two dPSMα2 nodal clusters constructed by merging MS data sets acquired 
from the CA-MRSA untreated and LL-37 treated extracts. Within each cluster the grey 
individual nodes indicate overlapping spectra found in both settings, the red nodes are represent 
spectra specific to LL-37 treatment and the gold nodes are spectra specific to the untreated 
sample. In the untreated CA-MRSA sample, four N-terminal truncated dPSMα2 were captured, 
including a 20-mer, the previously described 19-mer, a 17-mer, and a 12-mer (Fig. 3a). When 
treated with daptomycin, the molecular network map was able to group only the 20-mer and 19-
mer peptides. The 17-mer, 16-mer and 12-mer peptides were absent when treated with 
daptomycin (supplemental Fig. S10-S14). The dPSM variants captured in the LL-37 treated 
CA-MRSA sample mirrored the untreated sample, except the longer 20-mer and 19-mer were not 
present. Interestingly, the vancomycin treated sample abolished clustering of any dPSMα2 
peptides. Peptide abundance analysis via spectral counts for the clustered dPSMα2 peptides 
showed only the 19-mer was produced by the untreated CA-MRSA sample. Spectral counts for 
the daptomycin and LL-37 treated samples showed a significant increase in the abundance of all 
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four dPSMα2 peptides (Fig. 3b and supplemental Fig. S15). The spectral counts originating 
from the vancomycin treated sample only detected the 17-mer dPSMα2, consistent with previous 
reports on the effect of vancomycin treatment on PSMα type peptide production (29).  
Spectral Networks variants captured in PSMα4.  PSMα4 is a 20-mer peptide secreted 
with its initiator methionine in formylated and non-formylated forms. To date, two dPSMα4 have 
been discovered and tested for in vitro phenotypes. The variants of PSMα4, reminiscent of 
dPSMα1 and dPSMα2, showed increased antibacterial activity against Staphylococcus 
epidermidis and group A Streptococcus. Interestingly, dPSMα4 showed enhanced lytic activity 
against red blood cells. In addition, it was shown the S. aureus exoprotease aureolysin 
contributed to processing of PSMα4 into variant forms in vitro (18). When the theoretical masses 
for full-length PSMα4 formylated and non-formylated or dPSMs were sought in the CA-MRSA 
untreated molecular network, none were detected. Next, the daptomycin treated CA-MRSA 
molecular network was searched, resulting with the detection of full-length PSMα4 clustered 
with a 19-mer dPSMα4. Although, the 19-mer was clustered with PSMα4, the spectra quality did 
not allow de novo sequencing and therefore the peptide was not further considered. The 
daptomycin treated clusters also showed the presence of two additional dPSMα4, 17-mer and 15-
mer, previously reported (Fig. 3c and supplemental Fig. S10, S12). Neither the LL-37, nor the 
vancomycin-treated CA-MRSA showed node clusters indicative of dPSMα4 when theoretical 
masses were searched. Spectral counts of dPSMα4 showed the untreated sample produced 
detectable amounts of the 17-mer, but not the 15-mer peptide. In each case where CA-MRSA 
was treated with antibiotics, the increase of both dPSMα4, identified through molecular 
networking, were significantly increased (Fig. 3d and supplemental Fig. S16). 
 15 
Spectral Networks variants captured in PSMβ1 and PSMβ2.  PSMβ1 and PSMβ2 belong 
to the PSM peptide family but are almost twice as long as PSMα-type peptides. PSMβ1 and 
PSMβ2 are 44 amino acids in length, share high homology particularly in their C-terminal 
regions, and are more highly prevalent in CA-MRSA compared to HA-MRSA. PSMβ type 
peptides do not contribute to hemolysis in vitro and genetic disruption of the genes had 
negligible contributions to disease progression in a mouse model compared to the PSMα type 
members (13, 30). The PSMβ group is least well understood with respect to virulence 
contributions, but is postulated to contribute to biofilm structure formation (14). Furthermore, in 
contrast to the PSMα family, PSMβ variants (dPSMβ) have not been described. The molecular 
network map for the CA-MRSA untreated sample did not contain nodes indicative of either full-
length PSMβ1 or full-length PSMβ2. Instead only node clusters with masses corresponding to 
dPSMβ1 were identified. Four peptides consisting of a 19-mer, 18-mer, 17-mer, and a 16-mer 
contained accurate masses and reliable peptide sequence tags corresponding to truncated variants 
of PSMβ1 (Fig. 4a and 4b). Daptomycin and LL-37 treatment of CA-MRSA showed the 16-mer, 
present in the untreated sample, not to be clustered within the network. Treatment with 
vancomycin restored the clustering of the 16-mer dPSMβ1; however, the 17-mer dPSMβ1 
peptide found in the untreated sample was no longer detected. Interestingly, the network 
obtained from the vancomycin treated CA-MRSA was complex, dPSMβ1 variants with node 
masses that did not fit the known theoretical values or mass deviations due to common ion 
adducts were grouped together with sequenced peptides (Fig. 4A and supplemental Fig. S17-
S23). PSMβ2 showed clustering of two variants truncated at similar regions as dPSMβ1 that 
included the 19-mer and 18-mer peptides. In each molecular network map, the treatment with 
sub-MIC levels of any of the three antibiotic agents resulted in the node loss of the 19-mer 
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dPSMβ2 and revealed a 17-mer dPSMβ2 not present in the untreated molecular network (Fig. 4c 
and supplemental Fig. S17, S22-S26).  Spectral counts showed all clustered dPSMβ1 were 
present in the sample. Daptomycin treatment retained all observed dPSMβ1 peptides and 
enhanced the number of peptides for the 19-mer. Vancomycin also greatly enhanced the number 
of spectral counts for the 19-mer and did not detect any of the 17-mer peptide in successive runs. 
LL-37 treatment mirrored that of daptomycin and vancomycin (Fig. 4d and supplemental Fig. 
S27).  
Spectral Networks variants captured in PSMγ.  Delta-toxin or PSMγ is a highly expressed 
26-mer peptide exotoxin with the ability to lyse many cell types (31). PSMγ has been detected in 
its formylated and non-formylated forms in addition to one truncated dPSMγ peptide (18). PSMγ 
is of particular interest given the gene is embedded within the long studied RNAIII effector of 
the Agr quorum sensing system (32). In our work, PSMγ resulted in the most number of node 
clusters detected in the constructed molecular networks corresponding to dPSMγ. Fig. 5a shows 
a node cluster indicative of dPSMγ peptides derived from the molecular network map obtained 
by overlapping CA-MRSA +/- daptomycin. After searching through the all three sample maps, 
twelve N-terminal truncated dPSMγ peptides were clustered that included a 24-mer, previously 
described 23-mer, 22-mer, 21-mer, 20-mer, 19-mer, 18-mer, 15-mer, 10-mer, 9-mer, 8-mer, and 
a 7-mer (Fig. 5b and supplemental Fig. S28-S41). Daptomycin treatment of CA-MRSA did not 
perturb the variants clustered in the network, while LL37 treatment reduced our ability to cluster 
nodes indicative of the 19-mer, 18-mer, 15-mer, and the 7-mer dPSMγ peptides. Vancomycin 
treatment had a pronounced effect on the type of variants captured in the molecular networks, as 
only the 24-mer, 23-mer, 22-mer, and 20-mer were present. In addition, the clusters derived from 
vancomycin treatment had additional nodes that included masses that did not correspond to 
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theoretical dPSMγ values or the addition of common ion adducts; indicating potentially unknown 
posttranslational modifications (supplemental Fig. S41). dPSMγ spectral counts showed the 24-
mer, 15-mer, 9-mer, 8-mer and 7-mer were not detectable. Treatment with daptomycin restored 
all observed dPSMγ within the molecular network map and significantly increased the number of 
peptides in particular for the 21-mer and 20-mer peptides (Fig. 5c and supplemental Fig. S42). 
Vancomycin treatment significantly decreased the detection of the 21-mer dPSMγ peptide and 
did not match any of the 9-mer and 10-mer. LL-37 treatment yielded similar spectral counts to 
that of daptomycin, except the 9-mer peptide was not detected similar to the untreated sample. 
Bioactivity displayed by discovered dPSM. Previous reports demonstrated dPSMα-type 
had antimicrobial properties against bacteria that colonize human skin (17, 18). Based on these 
published reports, it was suggested dPSMs contribute to CA-MRSA success in out competing 
host microflora en route to establishing a suitable niche towards causing an infection. To 
reinforce the notion that the molecular network platform can be used as a tool to discover 
bioactive molecules, we selected to further study, in a functional manner, a pair of the indentified 
peptides: (i) +28MGIIAGIIKVIKS; formylated 13-mer dPSMα1 (ii) VSIVENGVGLLGKLFGF; 
nonformylated 17-mer dPSMβ1. Both peptides were of particular interest given C-terminally 
truncated dPSMs and dPSMβ-type peptides have not been reported nor studied for functional 
properties. We first sought to determine if the peptides contained antimicrobial activity against a 
library of bacteria known to colonize human skin; including strains that were previously shown 
to be susceptible to dPSMs (17, 18). The tested dPSM peptides did not alter the growth curves of 
the strains in successive experiments (Fig. 6a and supplemental Fig. S43a and S43b). In vitro, 
dPSMα-type has been shown to act as hemolysins and to synergize with the staphylococcal 
protein β-toxin, while in the in the same study, PSMβ-type did not contribute to hemolysis (30). 
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To test if the 13-mer dPSMα1 retained hemolytic properties once C-terminally cleaved or if the 
dPSMβ1 gained hemolytic potential once cleaved, both peptides were separately incubated with 
erythrocytes. In a dose dependent manner, both peptides showed a weak ability to act as 
hemolysins (Fig. 6b). Next we sought to determine if the human monocyte cell lines THP-1 
recognized and, in turn, were stimulated by the dPSMs by monitoring cytokine release. It was 
observed that dPSMα1 readily stimulated the release of IL-8 in a dose dependent manner (Fig. 
6c). When the dPSMβ1 peptide was tested for cytokine release, a similar release trend was 
observed when IL-1β was monitored (supplemental Fig. S43c). 
 
DISCUSSION 
 
 The current discovery rate of novel anti-staphylococcal therapeutics has not kept pace 
with the evolution of multi-resistant S. aureus strains of bona fide virulence potential (33). For 
this reason and others in the United States, S. aureus related deaths have been reported to 
approach or surpass those associated with HIV/AIDS (34). The high level of complexity and 
complementary nature of the biosynthetic release factors produced by S. aureus make it 
challenging to tease out the molecular basis of S. aureus infections. One contributing factor to 
this hurdle is the lack of available tools with the ability to capture biosynthetic release factors in 
a cooperative manner on a system-wide scale. Using the emerging tool of MS-based molecular 
networking, we constructed and investigated the biosynthetic release factor map of the leading 
CA-MRSA lineage associated with skin infections and sepsis in children and adults – USA300 
(35). Graphical maps of the constructed molecular networks indicate an abundance of 
biosynthetic release factors in the small molecule and peptide range (supplemental Fig. S44). 
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Recent reports have shown that PSMs contribute to biofilm fiber formation (14) and that 
truncated variant forms of PSMs gain antibacterial properties and/or modify host cell activities 
(17, 18). Therefore, we hypothesized the structural diversity of the PSMs family of peptides was 
more plentiful than previously reported. Using the molecular networking strategy, we were able 
to discover 34 dPSMs variants clustered in the molecular networks that were valid according to 
our set standards, only seven of which had been previously described in the literature. The 
number of captured dPSM variants varied when S. aureus was exposed to different 
pharmaceutical or natural antibiotics. The change in the spectrum of dPSMs most likely reflects 
concentration changes induced in response to environmental factors, consistent with previous 
studies showing antibiotic perturbations of PSM baseline expression levels (28). In addition, 
because of the inherent nature of spectral pairing, which molecular networking is based on, some 
spectra will not be clustered even if present in the sample. To give a broader perspective of the 
effect the tested antibiotics had on PSM production, spectral counts were enumerated by a 
traditional database matching strategy. As expected, we observed molecular networking and 
traditional database searching for PSM identification did not always correlate. Therefore, it can 
be concluded that the two MS data processing platforms are complementary and when applied 
give a more thorough representation of an organism’s biosynthetic potential. The recent literature 
on the topic of PSMs indicates this family of peptides has important, but not yet fully elucidated, 
roles during the course of S. aureus infection (16). We observed that clustered within the PSMs 
were additional masses that did not match to known theoretical PSMs, but had similar 
fragmentation patterns indicating related structural sequences. The clustering of inconclusive 
masses with PSMs identified with high confidence indicates PSMs may contain yet-to-be 
discovered post-translational modifications important for bioactivity or unidentified molecules 
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exist that are structurally similar. Astoundingly, the discoveries describing the PSM family of 
peptides herein are based on mining < 1% of the total molecular network in each case. 
Stimulation of IL-8 and IL-1β release from THP-1 cells demonstrates the peptides are bioactive 
in nature. We conclude the further development and application of tools such as MS-based 
molecular networking could steer new lines of discovery in the context of bacterial physiology, 
ecology or pathogenesis.  
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FIGURE LEGENDS 
 
Fig. 1.  Mass spectrometry-based molecular networking. CA-MRSA USA 300 strain 
TCH1516 was grown to late stationary phase alone or in the presence of antibiotic agents (1). 
The organic based solvent 1-butanol was used to extract small molecules and peptides from the 
CA-MRSA growth culture (2). The 1-butanol extract was brought to complete dryness by the use 
of a SpeedVac centrifuge (3). The solid extract was re-suspended in H2O and then components 
were separated by HPLC and directly electrosprayed into a Thermo Finnegan LTQ (4) for 
tandem MS analysis (5). The resulting data sets were processed by Spectral Networks (6), which 
compiles and clusters similar overlapping spectra based on similarly scores expressed as cosine 
values. A graphical representation of the clustered spectra population was displayed by the use of 
Cytoscape network maps. Individual tandem mass spectra are represented as circular nodes that 
are connected to other nodes with similar fragmentation patterns (7). Nodes within subpopulation 
clusters can be targeted based on theoretical parent ion masses. Once a validated node is 
identified (denoted as 1* in schematic), the structural information can be used as a building block 
to propagate and identify adjacent nodes in the cluster.  
 
Fig. 2. PSMα1 and related variants upon exposure to challenged conditions..  a, The  
molecular network resulting from ion clusters of PSMα1 is shown. Nodes colored blue are ion 
clusters found only in daptomycin challenged conditions. Nodes colored gold are found only in 
MRSA alone samples. Nodes colored grey are found in MRSA + daptomycin challenged 
conditions . Nodes labeled with only a sequence tag are within 500 ppm of the accurate 
theoretical mass. Nodes labeled with sequence tags plus (+) numbers have their mass accuracy 
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noted. A sub-nodal cluster of PSMα1 is also shown  with clusters from daptomycin (colored blue) 
and MRSA + daptomycin (colored grey). b, Sequence of PSMα1 is shown in bold followed by 
its related variants. c, Spectral counts for the formylated 13-mer peptide under respective 
challenged conditions. PSMα1 variants were not detected (ND) in the vancomycin treated 
sample. Analysis of the all nodes in the different conditions containing dPSMs is provided in 
Supplemental Information. 
 
Fig. 3.  PSMα2 and PSMα4 and related variants upon exposure to challenged conditions. a, 
The molecular network resulting from ion clusters of PSMα2 is shown, as well as the sequence 
for PSMα2 (shown in bold) and its variants. Nodes labeled with only a sequence tag are within 
500 ppm of the theoretical mass. Nodes labeled with sequence tags plus (+) numbers have their 
mass accuracy noted. Nodes colored grey are found in MRSA alone and MRSA + daptomycin. 
The nodes colored red found in LL-37 treated samples. The nodes colored gold are found in 
MRSA alone samples. b, The molecular network resulting from ion clusters of PSMα4 is shown, 
as well as the sequence for PSMα4 (shown in bold) and its variants. Nodes colored blue are ion 
clusters found only in daptomycin challenged conditions. Nodes labeled with only a sequence tag 
are within 500 ppm of the accurate mass. Nodes labeled with sequence tags plus numbers have 
their mass accuracy noted. c, PSMα2 variant IIAGIIKFIKGLIEKFTGK  peptide counts tested in 
replicates under respective conditions. PSMα2 variants were not observed in the vancomycin 
treated sample. d, PSMα4 variant TIIKIIKAIIDIFAK  peptide counts tested in  replicates under 
respective conditions. Analysis of the all nodes in the different conditions containing dPSMs is 
provided in Supplemental Information 
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Fig. 4.  PSMβ1, PSMβ2 and their related variants upon exposure to challenged conditions. 
a, The  molecular network resulting from ion clusters of PSMβ is shown. Nodes colored green 
are ion clusters found only in MRSA + vancomycin challenged conditions. Nodes colored gold 
are found only in MRSA samples. Nodes colored grey are found overlapping in MRSA alone 
samples and MRSA + daptomycin challenged conditions. Nodes labeled with only a sequence 
tag are within 500 ppm of the theoretical mass. Nodes labeled with sequence tags +numbers have 
their mass accuracy noted. b, PSMβ1 variant VSIVENGVGLLGKLFGF and the peptide counts 
tested in 3 replicates under respective conditions. c, Sequence of PSMβ1 (shown in bold) and 
related variants. Amino acid sequences for PSMβ1 are not shown in full form but are abbreviated 
at the N-terminal end. d, Sequence of PSMβ2 (shown in bold) and related variants. Amino acid 
sequences for PSMβ2 are not shown in full form but are abbreviated at the N-terminal end. 
Analysis of the all nodes in the different conditions containing dPSMs is provided in 
Supplemental Information 
 
Fig. 5.  PSMγ and related variants upon exposure to challenged conditions. a, The molecular 
network resulting from ion clusters of PSMγ is shown. Nodes colored blue are found in 
daptomycin challenged conditions. Nodes colored gold are found in MRSA only conditions. 
Nodes colored grey are found in MRSA + daptomycin challenged conditions. Nodes labeled with 
only a sequence tag are within 500 ppm of accurate mass. Nodes labeled with sequence tags plus 
numbers have their mass accuracy noted. b, The sequence for PSMγ is shown in bold followed 
by its variants. c, PSMγ variant ISTIGDLVKWIIDTVNKFTKK  peptide counts tested in 3 
replicates under respective conditions. Analysis of the all nodes in the different conditions 
containing dPSMs is provided in Supplemental Information 
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Fig. 6.  Bioactivity of the discovered dPSMα1 and dPSMβ1 peptides. a, Growth curve for 
Staphylococcus epidermis with and without dPSMβ1 measured at OD600 in 30 min increments 
over a 7.5 h period. b, Hemolytic assay performed with both dPSMα1 and dPSMβ1 and control 
(0.0125% Triton-X); results normalized to 0.0125% Triton-X and hemoglobin absorbance 
measured at 450 nm. Lane 1, 0.0125% Triton-X. Lane 2, 1µg/ml dPSMα1. Lane 3, 5µg/ml 
dPSMα1. Lane 4, 10µg/ml dPSMα1. Lane 5, 20µg/ml dPSMα1. Lane 6, 1µg/ml dPSMβ1. Lane 7, 
5µg/ml dPSMβ1. Lane 8, 10µg/ml dPSMβ1. Lane 9, 20µg/ml dPSMβ1. c, Enzyme-linked 
immunosorbent assay (ELISA) of human monocyte IL-8 response to dPSMα1 with IL-8 values 
in pg/ml and dPSMα1 concentration in µg/ml, performed in a dose dependent manner.  
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SIVSIVENGVGLLGKLFGF 
SIVSIVENGVGLLGKLFGF + 4 Da 
1300 Da 
IVSIVENGVGLLGKLFGF 
1919 Da 1620 Da 
1922 Da 
a. d. 
Figure 4 
a. 
b. c. 
PSMγ:	  +28MAQDIISTIGDLVKWIIDTVNKFTKK	  
QDIISTIGDLVKWIIDTVNKFTKK	  
TIGDLVKWIIDTVNKFTKK	  
ISTIGDLVKWIIDTVNKFTKK 
ISTIGDLVKWIIDTVNKFTKK + 2 Da 
AQDIISTIGDLVKWIIDTVNKFTKK 
QDIISTIGDLVKWIIDTVNKFTKK 
QDIISTIGDLVKWIIDTVNKFTKK – 15 Da 
QDIISTIGDLVKWIIDTVNKFTKK – 8 Da 
DIISTIGDLVKWIIDTVNKFTKK + 6 Da 
IISTIGDLVKWIIDTVNKFTKK  
DIISTIGDLVKWIIDTVNKFTKK + 2 Da 
ISTIGDLVKWIIDTVNKFTKK + 7 Da 
ISTIGDLVKWIIDTVNKFTKK + 8 Da 
ISTIGDLVKWIIDTVNKFTKK + 12 Da 
ISTIGDLVKWIIDTVNKFTKK + 10 Da 
IDTVNKFTKK	  
DTVNKFTKK	  
TVNKFTKK	  
	  IGDLVKWIIDTVNKFTKK	  
LVKWIIDTVNKFTKK	  
VNKFTKK	  
DIISTIGDLVKWIIDTVNKFTKK	  
IISTIGDLVKWIIDTVNKFTKK	  
	  STIGDLVKWIIDTVNKFTKK	  
ISTIGDLVKWIIDTVNKFTKK	  
Figure 5 
a. c. b. 
Figure 6 
